THYROCARE

on the move

delivered a strong Q2 FY26: consolidated revenue rose 22% YoY to ₹216.5 cr, and PAT surged 82% to ₹47.9 cr, while normalized EBITDA grew 49% YoY to ₹75.36 cr. They processed a record 53.3 million tests (+21% YoY), showing robust operational momentum. On the balance sheet, Thyrocare remains debt-free, with over ₹190 cr in net cash and short-term investments. The board has approved a 2:1 bonus issue and declared an interim dividend of ₹7/share, signaling confidence in sustained cash flows. Unlike many labs, Thyrocare’s strength lies in scale and automation — it’s not just growing, it's doing more tests efficiently with strong margins, giving it a unique operational edge.